Comparative Pharmacology
Head-to-head clinical analysis: LANTUS SOLOSTAR versus LEVEMIR FLEXTOUCH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANTUS SOLOSTAR versus LEVEMIR FLEXTOUCH.
LANTUS SOLOSTAR vs LEVEMIR FLEXTOUCH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glargine is a recombinant human insulin analog with prolonged duration of action. It binds to insulin receptors, activating downstream signaling pathways including PI3K/Akt, leading to increased glucose uptake in peripheral tissues, inhibition of hepatic gluconeogenesis, and promotion of glycogenesis and lipogenesis. The long-acting profile is due to precipitation at subcutaneous injection site with slow absorption.
Insulin analog that activates insulin receptors, promoting glucose uptake and inhibiting gluconeogenesis.
Injection, subcutaneous: initial: 0.2 units/kg once daily, typical maintenance: 0.5-1 unit/kg once daily, max: 80 units/day.
Subcutaneous injection, once or twice daily; starting dose 0.2-0.3 units/kg/day, titrate to target glycemic control.
None Documented
None Documented
Terminal elimination half-life is 12.5 hours (range 10-18 hours) after subcutaneous administration due to prolonged absorption from the injection site, reflecting the duration of action.
Terminal half-life: approximately 5-7 hours (subcutaneous injection). The prolonged half-life relative to regular human insulin is due to reversible albumin binding, providing a flat, prolonged pharmacokinetic profile. Clinically, this supports once- or twice-daily dosing.
Renal (minimal, intact drug not excreted), metabolized to inactive metabolites excreted renally and fecally; unchanged insulin glargine does not undergo significant renal excretion, degradation products excreted renally (~30%) and fecally (~70%).
Renal: approximately 50-70% of administered dose undergoes renal clearance as intact insulin; fecal: negligible (<10%). Insulin detemir is extensively metabolized in the liver (via dipeptidyl peptidase IV and other proteolytic enzymes) and the kidney, with metabolites excreted in urine.
Category C
Category C
Long-Acting Insulin
Long-Acting Insulin